Latest / Glaucoma, Vision & Longevity: Supplements & Science / Could Rhopressa Protect the Optic Nerve, Not Just Lower Eye Pressure? A New Trial Will Count Individual Glaucoma Nerve Cells

Transcript

Could Rhopressa Protect the Optic Nerve, Not Just Lower Eye Pressure? A New Trial Will Count Individual Glaucoma Nerve Cells · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Could ropressa protect the optic nerve, not just lower eye pressure?
• 0:04
  SPEAKER_00: A new trial will count individual glaucoma nerve cells.
• 0:08
  SPEAKER_00: A newly registered study is asking an unusually direct question.
• 0:12
  SPEAKER_00: Does netarseudal ropresa preserve retinal nerve cells better than timolol when used by people with open-angle glaucoma?
• 0:20
  SPEAKER_00: Rather than relying only on standard scans that measure the thickness of broad retinal layers, the researchers plan to use adaptive optics optical coherence tomography to image and count cells in the living eye.
• 0:32
  SPEAKER_00: It is an exciting idea, but this is a small, early clinical test, not proof that ropressa protects the optic nerve independently of pressure.
• 0:41
  SPEAKER_00: The trial's design, its short treatment periods, and unresolved questions about the new imaging method all matter.
• 0:48
  SPEAKER_00: So does a fundamental challenge.
• 0:50
  SPEAKER_00: Two medicines can produce similar pressure readings in the clinic while having different effects on pressure overnight, blood flow, or pressure variability.
• 0:59
  SPEAKER_00: The new trial, what is registered, the phase four study, NCT 07847073, is titled Adaptive Optics OCT Evaluation of Ropress's effects on the retinal ganglion cells in glaucoma patients.
• 1:14
  SPEAKER_00: It was first posted on September 29, 2026, after submission on September 22nd.
• 1:19
  SPEAKER_00: The registry lists it as recruiting with an estimated start date of October 1st, 2026.
• 1:25
  SPEAKER_00: That estimated date is not confirmation that the first participant was enrolled on that day.
• 1:30
  SPEAKER_00: The planned study completion date is January 1st, 2028.
• 1:35
  SPEAKER_00: Clinicaltrials.gov Study Record.
• 1:37
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 1:42
  SPEAKER_00: The two treatment regimens are netarcidal 0.02%, one drop in the study eye once daily in the evening for six months, TMAL male 8.25%, one drop in the study eye twice daily, morning and evening for six months.
• 1:56
  SPEAKER_00: One group receives netarcudal first and then Tolol.
• 2:00
  SPEAKER_00: The other receives TMALAL first and then netarcudal.
• 2:02
  SPEAKER_00: Trial interventions and outcomes.
• 2:05
  SPEAKER_00: Who can take part and what the registry does not say?
• 2:09
  SPEAKER_00: Participants must be at least 18 years old and have open angle glaucoma with structural damage to the optic nerve or retinal nerve fiber layer, plus matching visual field defects.
• 2:21
  SPEAKER_00: Corrected visual acuity must be 2050 or better, and participants must be able to fixate for imaging.
• 2:28
  SPEAKER_00: The allowed refractive range is a spherical equivalent from plus 3 to minus 6 diopters with cylinder under 3 diopters.
• 2:35
  SPEAKER_00: People who are new to pressure-lowering drops or who have completed a medication washout must have an intraocular pressure between 18 and 34 millimeters of mercury.
• 2:46
  SPEAKER_00: The record excludes people with certain other retinal diseases or optic nerve conditions or who cannot safely undergo washout.
• 2:54
  SPEAKER_00: It does not state a formal glaucoma severity category, such as mild, moderate, or advanced, nor does it publish the washout duration or specify different washout periods for different medicines.
• 3:06
  SPEAKER_00: The record describes a switch at month six, but does not specify a separate washout between treatment periods.
• 3:14
  SPEAKER_00: Eligibility criteria and study arms.
• 3:17
  SPEAKER_00: That missing information matters.
• 3:19
  SPEAKER_00: A medication-free pressure reading after washout establishes eligibility, but it does not prove that participants will have the same pressure exposure on both study medicines.
• 3:29
  SPEAKER_00: And an immediate switch at month six, if that is what happens, would be different from a design with a defined washout between periods.
• 3:37
  SPEAKER_00: Why a crossover design helps, and why it is awkward here.
• 3:41
  SPEAKER_00: A crossover can be efficient in a small study because each participant receives both medicines.
• 3:47
  SPEAKER_00: Each person therefore serves as their own comparison, reducing the influence of differences such as age, starting cell density, and individual disease severity.
• 3:56
  SPEAKER_00: But glaucoma nerve cell loss creates a serious crossover problem.
• 4:00
  SPEAKER_00: Dead nerve cells do not come back when a treatment period ends.
• 4:04
  SPEAKER_00: A washout may reduce the immediate pressure-lowering effect of a drop, but it cannot wash out accumulated neuronal injury or any lasting biological effect on survival.
• 4:15
  SPEAKER_00: The second six-month period also always occurs later in time when a participant's disease may have progressed further.
• 4:22
  SPEAKER_00: Randomizing treatment order helps balance this period effect across the group, but with only 13 participants, the two treatment sequences will be small.
• 4:31
  SPEAKER_00: Other concerns include carryover, a medicine's pressure effects may fade after stopping, but a lasting effect on cell health or a lasting harmful effect could remain.
• 4:42
  SPEAKER_00: Washout risk.
• 4:43
  SPEAKER_00: Stopping glaucoma treatment can raise pressure.
• 4:46
  SPEAKER_00: The registry says washout is required for some participants but does not state the duration.
• 4:52
  SPEAKER_00: Unequal periods.
• 4:53
  SPEAKER_00: Retinal damage may progress at a different rate in different months or in different retinal locations.
• 4:59
  SPEAKER_00: A change during the second period may not be fairly compared with a change during the first.
• 5:04
  SPEAKER_00: Irreversible measurement.
• 5:06
  SPEAKER_00: If cells were lost in period one, that loss remains in period two.
• 5:11
  SPEAKER_00: A later treatment cannot restore the original starting count.
• 5:15
  SPEAKER_00: The design is reasonable for an exploratory study, but it is not an easy way to isolate the effects of two treatments on a slow, irreversible disease.
• 5:24
  SPEAKER_00: Why counting individual cells is different from a standard glaucoma scan?
• 5:29
  SPEAKER_00: Routine optical coherence tomography is a central tool in glaucoma care.
• 5:34
  SPEAKER_00: It commonly measures the retinal nerve fiber layer, which contains ganglion cell axons, and the thickness of the ganglion cell interplexiform layer or the ganglion cell complex.
• 5:45
  SPEAKER_00: These measurements are valuable, but they are measurements of layers, not counts of living nerve cell bodies.
• 5:51
  SPEAKER_00: A layer's thickness can be affected by several tissue components and does not always tell us whether an individual cell has died.
• 5:59
  SPEAKER_00: Adaptive optics optical coherence tomography combines two imaging ideas.
• 6:04
  SPEAKER_00: Optical coherence tomography produces depth-resolved cross-sectional images of retinal tissue.
• 6:10
  SPEAKER_00: Adaptive optics measures and corrects distortions caused by the eye's own optical imperfections using a deformable mirror to sharpen the image.
• 6:18
  SPEAKER_00: The result can show structures only a few micrometers across.
• 6:23
  SPEAKER_00: Published research systems have reported three-dimensional resolution around 2.4s, 2.4, 4.7 micrometers.
• 6:31
  SPEAKER_00: Another research grade system reported a theoretical lateral resolution of 2.5 micrometers and a nominal depth resolution of 3.7 micrometers.
• 6:41
  SPEAKER_00: Researchers have used these systems to image the ganglion cell layer at small macular locations, generally in fields about 1.5 degrees across, at retinal locations ranging from near the fovea to roughly 12 to 13 degrees away.
• 6:56
  SPEAKER_00: Foundational Adaptive Optics Imaging Study and Research on Imaging Ganglion cell somas.
• 7:01
  SPEAKER_00: Can it really identify and track the same cells?
• 7:04
  SPEAKER_00: Researchers can often recognize cell-like structures by their size, shape, depth, reflectance, and position relative to other retinal landmarks.
• 7:13
  SPEAKER_00: They register images from repeated scans, aligning them to the same tissue locations, and average many registered images to reduce speckle and sharpen cell outlines.
• 7:24
  SPEAKER_00: In one early study, averaging roughly 100 to 160 registered image volumes improved the visibility of ganglion cell layer somas.
• 7:33
  SPEAKER_00: Imaging and quantifying ganglion cells, there is proof of feasibility, but not yet a large, validated clinical method for tracking cell death.
• 7:42
  SPEAKER_00: In one glaucoma case followed for two years, an adaptive optics study reported declining soma counts in four small regions of an arcuate defect.
• 7:51
  SPEAKER_00: The estimated annual losses differed across regions, from 3.1% to 6.2%.
• 7:57
  SPEAKER_00: This was a conference abstract about one participant, not a large longitudinal validation study.
• 8:03
  SPEAKER_00: 2023 Study Abstract.
• 8:05
  SPEAKER_00: There is also an important distinction between seeing a soma in the ganglion cell layer and proving that it is a retinal ganglion cell.
• 8:13
  SPEAKER_00: Current images identify cells by anatomy and appearance, not by a molecular label.
• 8:18
  SPEAKER_00: The ganglion cell layer contains a small number of other cell types, including displaced amacrels, and the living image may not always reveal a cell's identity with certainty.
• 8:29
  SPEAKER_00: Researchers have also imaged glial cells and macrophage-like cells elsewhere in the retina.
• 8:35
  SPEAKER_00: The imaging method is promising, but individual ganglion cell counts should not be understood as molecularly confirmed identification of every cell.
• 8:44
  SPEAKER_00: Research review of adaptive optics imaging and study of presumed displaced ganglion cells.
• 8:50
  SPEAKER_00: Eye motion is another challenge.
• 8:52
  SPEAKER_00: Even small eye movements can misalign images at cellular scale.
• 8:56
  SPEAKER_00: Image registration helps correct motion, but it is a necessary processing step, not a guarantee that repeated visits sample precisely the same cells.
• 9:06
  SPEAKER_00: Scan quality, fixation, optical clarity, and the ability to reproduce retinal locations all affect the count.
• 9:13
  SPEAKER_00: A related repeatability study gives a useful warning.
• 9:16
  SPEAKER_00: When researchers recounted bright, large, presumed, displaced ganglion cells at seven locations in one healthy participant six months apart, the reported 95% limits of agreement were about mice of 24.8%.
• 9:30
  SPEAKER_00: That result is not a direct estimate of how this glaucoma trial's primary outcome will perform.
• 9:35
  SPEAKER_00: It involved a small sample and a different cell population.
• 9:38
  SPEAKER_00: But it shows why a cell-resolved image is not automatically a low noise measurement.
• 9:43
  SPEAKER_00: A robust, widely replicated estimate of the smallest detectable change for the trial's exact method is not yet established.
• 9:51
  SPEAKER_00: Repeatability report.
• 9:53
  SPEAKER_00: Advanced glaucoma and high myopia.
• 9:56
  SPEAKER_00: The registry does not set a formal glaucoma severity cutoff.
• 10:00
  SPEAKER_00: However, the acuity and fixation requirements may make imaging difficult for some people with advanced disease.
• 10:06
  SPEAKER_00: In areas where cell density is already very low, small changes can be harder to count reliably.
• 10:12
  SPEAKER_00: Poor fixation or severe damage may also make a scan unusable.
• 10:16
  SPEAKER_00: High myopia is restricted by the study's refractive limits.
• 10:20
  SPEAKER_00: Prescriptions more myopic than minus six diopters are outside the listed range.
• 10:25
  SPEAKER_00: That is relevant both for eligibility and measurement.
• 10:28
  SPEAKER_00: Highly myopic eyes can have altered retinal geometry and greater optical or registration challenges.
• 10:34
  SPEAKER_00: The study's results, therefore, may not apply to people with high myopia.
• 10:38
  SPEAKER_00: The registry does not state the exact retinal locations, field sizes, number of scans per location, or cell matching rules planned for the trial.
• 10:48
  SPEAKER_00: Those details would be important for interpreting any result.
• 10:52
  SPEAKER_00: Is there a biological case for roe associated protein kinase inhibition protecting nerve cells?
• 10:57
  SPEAKER_00: There is a plausible biological story.
• 11:00
  SPEAKER_00: Rhoe-associated protein kinases help regulate a cell's internal scaffolding and processes such as movement, cell survival, and axon growth.
• 11:09
  SPEAKER_00: Inhibiting these enzymes may reduce some injury pathways and make it easier for damaged nerve fibers to grow.
• 11:15
  SPEAKER_00: But most evidence for protection of retinal ganglion cells comes from laboratory and animal studies, not from clinical trials showing that people with glaucoma lose fewer nerve cells.
• 11:26
  SPEAKER_00: What animal studies suggest.
• 11:29
  SPEAKER_00: Several compounds in this drug class have produced encouraging results.
• 11:33
  SPEAKER_00: Netarseutal.
• 11:34
  SPEAKER_00: In a rat optic nerve crush experiment, topical netarseudil was applied three times daily for 14 days.
• 11:41
  SPEAKER_00: Treated animals had greater retinal ganglion cell survival and more axons extending beyond the injury than controls.
• 11:48
  SPEAKER_00: Treatment also changed markers of rho kinase activity in the retina and the nearby optic nerve.
• 11:54
  SPEAKER_00: The experiment was an acute injury model in young rats, not chronic human glaucoma, and it did not cleanly separate pressure effects from direct nerve effects.
• 12:03
  SPEAKER_00: Natarsudal optic nerve injury study.
• 12:06
  SPEAKER_00: Reposeudal topical treatment has protected retinal ganglion cells in animal models of raised pressure and optic nerve injury.
• 12:14
  SPEAKER_00: A newer study reported effects on injury-related pathways in the retina and optic nerve, including in a model where treatment did not change the pressure rise.
• 12:24
  SPEAKER_00: That makes a pressure-independent effect more plausible in animals, but still does not establish one in people.
• 12:31
  SPEAKER_00: Mechanism study.
• 12:33
  SPEAKER_00: Fasudal and other inhibitors.
• 12:35
  SPEAKER_00: Studies report reduced retinal cell death, reduced inflammation, changes in programmed cell death pathways, and improved optic nerve blood flow in some animal models.
• 12:45
  SPEAKER_00: Other experiments have found inconsistent regeneration results, including differences by species and delivery method.
• 12:52
  SPEAKER_00: Systematic review of ocular rho kinase inhibition.
• 12:56
  SPEAKER_00: The evidence includes axonal regeneration after optic nerve injury, not just cell survival.
• 13:01
  SPEAKER_00: Rochinase inhibition can promote axon growth in experimental systems.
• 13:06
  SPEAKER_00: That is biologically important, but it is not the same as showing that a person with chronic glaucoma regains useful vision.
• 13:13
  SPEAKER_00: A growing axon must reconnect appropriately, and animal crush injuries do not reproduce years of human disease.
• 13:20
  SPEAKER_00: Some regeneration experiments have also reported abnormal or sparse dendritic structures.
• 13:25
  SPEAKER_00: Review of regeneration evidence.
• 13:28
  SPEAKER_00: Does topical ropressa deliver enough drug to the back of the eye?
• 13:32
  SPEAKER_00: This is the translational question the animal findings cannot answer on their own.
• 13:36
  SPEAKER_00: In rabbits, a single topical dose of 0.02% radiolabeled netarsidol produced a maximum of about 50 to 80 nanograms of drug-related radioactivity per gram in retinochoroid tissue.
• 13:49
  SPEAKER_00: The peak occurred within about half an hour.
• 13:51
  SPEAKER_00: By comparison, concentrations were far higher in the cornea and conjunctiva.
• 13:56
  SPEAKER_00: The measurement represents total radiolabel, not a direct measurement of free active drug inside retinal ganglion cells.
• 14:04
  SPEAKER_00: Netarseudal pharmacokinetics study, as a rough illustration only, if all of that radioactivity were intact, netarseutal and one gram of tissue were treated as roughly 1 milliliter, 50-80 nanograms per gram would correspond to around 0.1 to 0.2 micromolar.
• 14:21
  SPEAKER_00: That conversion should not be mistaken for an observed concentration of active drug at the nerve cells.
• 14:27
  SPEAKER_00: The radioactivity can include drug-related material other than the active parent compound, and the free concentration at the relevant cells is unknown.
• 14:37
  SPEAKER_00: Netarseutil is converted in the cornea to an active metabolite called AR350O3, which is more potent than the parent drug in certain laboratory assays.
• 14:47
  SPEAKER_00: But animal tissue distribution results do not tell us exactly how much active metabolite reaches human retinal ganglion cells.
• 14:56
  SPEAKER_00: Human systemic levels after topical dosing are very low or below measurement limits.
• 15:01
  SPEAKER_00: That does not measure drug concentration in the human retina or optic nerve.
• 15:06
  SPEAKER_00: United States Food and Drug Administration Pharmacology Review.
• 15:10
  SPEAKER_00: The strongest exposure argument for nitarsudil is that topical dosing produced protective effects in some animal injury models and changed pathway markers in posterior eye tissues.
• 15:21
  SPEAKER_00: The main limitation is that these studies do not supply the crucial human bridge, a measured concentration of active nitarsudil or AR-3503 in the human retina or optic nerve linked to a neuroprotective concentration in that tissue.
• 15:36
  SPEAKER_00: Some experimental protective effects with other inhibitors have been studied at high concentrations.
• 15:41
  SPEAKER_00: For example, one review describes an experiment using 100 micromolar reposudil in a mouse retinal injury model.
• 15:50
  SPEAKER_00: That is not a direct comparison with netarseutal, and it cannot be used to rule netarseutal in or out.
• 15:57
  SPEAKER_00: It does underscore why a general statement that rokyase inhibitors protect neurons in the laboratory is not enough to prove that an eye drop delivers an effective dose to human nerve cells.
• 16:08
  SPEAKER_00: Review of rokinase inhibitor neuroprotection, netarsudal versus timolol, similar clinic readings may not mean similar pressure exposure.
• 16:17
  SPEAKER_00: A comparison against timolol is sensible, both medicines' lower pressure and earlier large trials found once daily netarsudal, broadly non-inferior to twice daily timolol, for daytime pressure measurements in a particular patient population.
• 16:32
  SPEAKER_00: But that does not prove equal pressure exposure across the full day and night, and those trials use Timolol.5%, while NCT0784773 uses 0.25%.
• 16:43
  SPEAKER_00: Rocket 4 trial.
• 16:45
  SPEAKER_00: Timolol mainly lowers pressure by reducing fluid production in the eye.
• 16:49
  SPEAKER_00: Its pressure-lowering effect can be weaker overnight, and it may also lower heart rate or blood pressure in some people.
• 16:56
  SPEAKER_00: In one 24-hour study of people with normal tension glaucoma, timolol lowered blood pressure and heart rate, while mean ocular perfusion pressure did not significantly improve.
• 17:07
  SPEAKER_00: 24-hour timolol comparison.
• 17:10
  SPEAKER_00: Nitarsudal has been shown to reduce nighttime pressure in a small clinical study.
• 17:14
  SPEAKER_00: It also has effects on the eye's drainage pathway and episcleral veins that timolol does not share in the same way.
• 17:22
  SPEAKER_00: 24-hour netarsudal study.
• 17:25
  SPEAKER_00: So even if office pressure readings look similar, the treatments could differ in nighttime pressure, pressure peaks in day-to-day fluctuation, pressure while lying down, episcleral venous pressure, blood pressure, heart rate, and the blood supply available to the optic nerve.
• 17:42
  SPEAKER_00: Any of these differences could influence nerve cell survival.
• 17:45
  SPEAKER_00: Some would be indirect protection through pressure or blood flow changes, not proof that natarsudal directly makes retinal ganglion cells more resistant to injury.
• 17:56
  SPEAKER_00: Other effects that might help or complicate interpretation.
• 18:00
  SPEAKER_00: Nitarsudal increases outflow through the eye's trabecular drainage pathway.
• 18:05
  SPEAKER_00: In a small study of healthy volunteers, it increased outflow facility by about 22% and lowered episcoral venous pressure by about 10% from baseline.
• 18:15
  SPEAKER_00: Those are human findings about the eye's drainage system, not proof of improved optic nerve blood flow.
• 18:22
  SPEAKER_00: Human aqueous humor dynamics study.
• 18:24
  SPEAKER_00: Rokinase inhibitors may also alter blood vessel behavior.
• 18:28
  SPEAKER_00: Animal results suggest possible effects on optic nerve circulation, while limited human studies have examined blood flow in episcoral veins.
• 18:36
  SPEAKER_00: Improved blood flow in those surface veins does not demonstrate improved blood flow at the optic nerve head.
• 18:42
  SPEAKER_00: The class also has effects on the cornea.
• 18:45
  SPEAKER_00: Rochinase inhibition can support corneal endothelial cell repair in some settings, but netarseutal can cause corneal side effects, including a characteristic honeycomb-like swelling in people with compromised corneas.
• 19:00
  SPEAKER_00: These effects do not provide a convincing direct route to retinal ganglion cell protection.
• 19:05
  SPEAKER_00: Corneal changes can also complicate pressure measurements or image quality.
• 19:09
  SPEAKER_00: How this fits with other proposed glaucoma neuroprotective treatments.
• 19:14
  SPEAKER_00: The search for protection beyond pressure lowering has produced several promising ideas, but no established medication that replaces pressure control.
• 19:23
  SPEAKER_00: Bramonidine.
• 19:25
  SPEAKER_00: The low pressure glaucoma treatment study reported less visual field progression among participants who remained on bromonidine than among those taking timolol, despite similar measured pressure.
• 19:37
  SPEAKER_00: But many more participants stopped bromonidine, often because of allergy.
• 19:41
  SPEAKER_00: That uneven dropout makes the result difficult to interpret, and the timolol comparator raises questions about possible nighttime blood pressure or perfusion effects.
• 19:52
  SPEAKER_00: A Cochrane review concluded that the evidence was too uncertain to establish a neuroprotective benefit.
• 19:58
  SPEAKER_00: Cochrane review of glaucoma neuroprotection, nicotinamide and pyruvate.
• 20:03
  SPEAKER_00: These aim to support cellular energy metabolism.
• 20:06
  SPEAKER_00: A short randomized study found short-term improvement in some measures of retinal function, but improvement in function is not the same as proof that cells die more slowly.
• 20:16
  SPEAKER_00: Longer studies are needed to establish preservation of vision in cells.
• 20:20
  SPEAKER_00: Randomized nicotinamide and pyruvate study, G01, or recombinant human nerve growth factor variant 2.
• 20:28
  SPEAKER_00: This is an investigational nerve growth factor approach.
• 20:32
  SPEAKER_00: Its developer reported that an application to begin clinical testing in China received a trial authorization in November 2024.
• 20:40
  SPEAKER_00: That is an early development milestone, not evidence of clinical benefit.
• 20:45
  SPEAKER_00: Developer announcement Ciliary Neurotrophic Factor and the NT501 implant.
• 20:51
  SPEAKER_00: An early phase one study implanted a device that releases ciliary neurotrophic factor in 11 people with glaucoma.
• 20:58
  SPEAKER_00: It reported safety and possible structural or functional signals, but its size and design cannot establish effectiveness.
• 21:04
  SPEAKER_00: Phase 1 NT501 study, ASP 767.
• 21:09
  SPEAKER_00: Estellus lists a phase 1 half program for this investigational treatment of glaucoma-related optic nerve damage.
• 21:16
  SPEAKER_00: It is at a different early stage and uses an injection-based study design.
• 21:21
  SPEAKER_00: The existence of a trial is not evidence that it protects vision.
• 21:24
  SPEAKER_00: Estellos trial information.
• 21:27
  SPEAKER_00: ER-100, on October 8, 2026, its developer announced interim first-in-human results in three participants with glaucoma.
• 21:36
  SPEAKER_00: Treatment was reported as tolerated through day 56, with preliminary visual field signals in two participants.
• 21:43
  SPEAKER_00: These are sponsor reported results from a very small early phase study, not proof of benefit.
• 21:49
  SPEAKER_00: Company announcement Cytokoline and Coenzyme Q10.
• 21:53
  SPEAKER_00: Some small studies report changes in visual function or electrical responses from the retina.
• 21:58
  SPEAKER_00: A systematic review of Cytocholine studies found insufficient evidence that it slows glaucoma progression.
• 22:04
  SPEAKER_00: Coenzyme Q10 studies have also reported promising signals, but these have not established that it preserves retinal ganglion cells or vision over time.
• 22:14
  SPEAKER_00: Cytocholine Systematic Review and Coenzyme Q10 study.
• 22:18
  SPEAKER_00: The lesson from these approaches is that an appealing mechanism, a laboratory result, or a short-term improvement in a test is not enough.
• 22:27
  SPEAKER_00: A convincing trial needs to show that the treatment preserves nerve cells or vision while accounting for differences in pressure exposure and other treatment effects.
• 22:37
  SPEAKER_00: Could a 13-person trial detect a real change?
• 22:40
  SPEAKER_00: A very small study is not automatically useless.
• 22:44
  SPEAKER_00: Adaptive optics can potentially count hundreds or thousands of cells in a small retinal area, and the crossover design gives each participant a comparison with themselves.
• 22:54
  SPEAKER_00: Those features may help a study detect a biological signal sooner than a trial relying only on broad layer thickness or visual field change.
• 23:02
  SPEAKER_00: But the number of cells imaged is not the same as the number of independent participants.
• 23:08
  SPEAKER_00: Cells from one person share the same eye, disease, treatment adherence, and biology.
• 23:14
  SPEAKER_00: Treating every counted cell as an independent person would exaggerate how much information the study contains.
• 23:20
  SPEAKER_00: The scale of the expected change is also an issue.
• 23:24
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 23:29
  SPEAKER_00: These are not interchangeable measurements.
• 23:31
  SPEAKER_00: Healthy aging estimates come from different approaches, and rates based on retinal nerve fiber layer or ganglion cell layer thickness are not identical to directly counted soma loss.
• 23:42
  SPEAKER_00: The reported 3.1% to 6.2% rate is from one person's small imaged regions, not a general estimate for all people with glaucoma.
• 23:51
  SPEAKER_00: Aging-related ganglion cell estimates, glaucoma progression estimates, and adaptive optics glaucoma abstract.
• 23:58
  SPEAKER_00: For perspective, a 1.5 degree field near the macula may contain thousands of visible somas.
• 24:04
  SPEAKER_00: If a region contains 4,000 somas and loses 2.5% in six months, that is about 100 fewer.
• 24:11
  SPEAKER_00: If a treatment have that loss, the difference would be about 50 somas.
• 24:15
  SPEAKER_00: This is a simplified illustration, not a prediction for this trial.
• 24:19
  SPEAKER_00: Actual cell density, scan location, image quality, disease rate, and counting rules all matter.
• 24:26
  SPEAKER_00: The potential advantage is that a correctly registered image might reveal particular cells that are no longer visible at a later visit.
• 24:33
  SPEAKER_00: The problem is that current repeatability data are limited, and a difference of less than a few percent over six months could be hard to distinguish from changes in image quality, registration, or cell visibility.
• 24:46
  SPEAKER_00: A negative result in 13 people would therefore not rule out a modest benefit.
• 24:51
  SPEAKER_00: My judgment, the study has a real chance of producing useful feasibility data and perhaps a striking signal in a fast progressing region.
• 25:00
  SPEAKER_00: It has a much smaller chance of giving a reliable estimate of netarsidil's protective effect across people with glaucoma.
• 25:08
  SPEAKER_00: What would be needed to prove pressure-independent neuroprotection?
• 25:11
  SPEAKER_00: A positive result would be much more persuasive if a larger, longer study compared pressure exposure over the full day and night, not just a few clinic readings, measured or carefully accounted for pressure peaks and fluctuation, treatment adherence, blood pressure, and heart rate.
• 25:29
  SPEAKER_00: Used the same imaged retinal locations at every visit and published detailed scan and cell matching procedures.
• 25:37
  SPEAKER_00: Established repeatability and the smallest detectable change for the exact imaging method before interpreting treatment effects, included enough participants and enough follow-up to separate treatment effects from progression over time.
• 25:51
  SPEAKER_00: Confirmed the cell count findings with other measures, such as standard retinal imaging and visual function, showed that any advantage remained after pressure exposure was matched or appropriately adjusted.
• 26:04
  SPEAKER_00: Even then, a treatment might protect cells indirectly, for example, by changing nighttime pressure or blood flow, rather than by acting directly inside retinal ganglion cells.
• 26:14
  SPEAKER_00: Both mechanisms could be clinically useful, but they are different scientific claims.
• 26:20
  SPEAKER_00: Evidence, strong inference, and speculation.
• 26:23
  SPEAKER_00: Evidence natarsudal lowers pressure and has effects on the eye's drainage system.
• 26:28
  SPEAKER_00: In animal models, topical natarsudal and other roe-associated protein kinase inhibitors have shown retinal cell survival or axon regeneration effects.
• 26:38
  SPEAKER_00: Research adaptive optics systems can image ganglion cell layer somas in living human eyes.
• 26:43
  SPEAKER_00: The new trial is randomized, uses both medicines in each participant, and plans only 13 participants with six months on each treatment.
• 26:52
  SPEAKER_00: Strong inference.
• 26:53
  SPEAKER_00: The trial can test whether the imaging method can be used repeatedly in a small clinical study.
• 26:59
  SPEAKER_00: A simple daytime pressure comparison will not be enough to establish equal pressure exposure on netarseudil and timolol.
• 27:06
  SPEAKER_00: The crossover is efficient for a small study but vulnerable to time trends and lasting effects because neuronal loss is irreversible.
• 27:15
  SPEAKER_00: Any apparent netarsutal advantage could reflect pressure timing, blood flow effects, or measurement differences rather than direct cellular protection.
• 27:24
  SPEAKER_00: Speculation, and my probability estimates among, these are reasoned judgments, not outputs of a validated statistical model.
• 27:32
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 27:36
  SPEAKER_00: The biological case is credible, and the animal findings are more than a bare laboratory curiosity.
• 27:42
  SPEAKER_00: But the human evidence is still missing.
• 27:45
  SPEAKER_00: The retinal dose of active drug is unknown, and this trial is not designed to prove equal 24-hour pressure exposure or a direct cellular mechanism.
• 27:54
  SPEAKER_00: Could Ropressa already be doing more than lowering eye pressure?
• 27:58
  SPEAKER_00: Possibly, but it is not established.
• 28:01
  SPEAKER_00: Netarseutil reaches the back of the eye in animal studies in small amounts of drug-related material, and topical treatment has protected nerve cells or promoted axon growth in some animal injury models.
• 28:13
  SPEAKER_00: Its effects on drainage and episcleral veins could also alter pressure or blood flow conditions in ways that help the nerve.
• 28:21
  SPEAKER_00: The clinical problem is separating those effects.
• 28:24
  SPEAKER_00: If netharseudal preserves more cells than timolol, the result would be promising.
• 28:30
  SPEAKER_00: It would not by itself prove direct neuroprotection independent of pressure.
• 28:35
  SPEAKER_00: The medicines may produce different pressure levels overnight, different pressure fluctuations, or different effects on blood pressure and ocular perfusion.
• 28:44
  SPEAKER_00: And the available human evidence does not yet show that netarsutil preserves retinal ganglion cells better than another pressure-lowering drop.
• 28:52
  SPEAKER_00: The bigger breakthrough may be seeing individual nerve cells die.
• 28:57
  SPEAKER_00: Adaptive optics imaging could ultimately matter as much as the drug being tested.
• 29:02
  SPEAKER_00: Conventional retinal scans infer change from the thickness of broad layers.
• 29:07
  SPEAKER_00: A cell-resolved scan may instead make it possible to follow the same small retinal region and potentially the same cells over time.
• 29:17
  SPEAKER_00: If larger studies show that these counts are repeatable, specific, and sensitive to treatment, researchers may be able to detect biological effects sooner than they can with visual field change or broad structural measurements.
• 29:29
  SPEAKER_00: That could help future trials screen treatments more quickly and make early studies more informative.
• 29:36
  SPEAKER_00: For now, that is a promising possibility, not a proven shortcut.
• 29:40
  SPEAKER_00: The important advance in this 13-person trial may be whether researchers can reliably count the same nerve cell layer somas over repeated visits and learn how much change is real rather than noise.
• 29:53
  SPEAKER_00: All links to sources are available in the text version of this article.
• 29:58
  SPEAKER_00: You can find the full article at visualfieldtest.com.
• 30:01
  SPEAKER_00: Thanks for listening.
• 30:03
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.